cb-r

CBR-5884 是一种磷酸甘油酸脱氢酶抑制剂，IC50为 33 μM。 它抑制癌细胞中的丝氨酸合成，选择性地抑制黑素瘤和乳腺癌细胞系的增殖，对具有高丝氨酸生物合成活性的癌细胞系有选择性毒性。

CBR-2092 is a DNA-directed RNA polymerase and DNA topoisomerase inhibitor. CBR-2092 exhibited rifampin-like potency as an inhibitor of RNA polymerase, was an equipotent (balanced) inhibitor of DNA gyrase and DNA topoisomerase IV, and retained activity against a prevalent quinolone-resistant variant. Studies of mutant strains that exhibited reduced susceptibility to CBR-2092 further substantiated RNA polymerase as the primary cellular target of CBR-2092, with DNA gyrase and DNA topoisomerase IV being secondary and tertiary targets, respectively, in strains exhibiting preexisting rifampin resistance.

CBR-470-2, a glycine-substituted analog, exhibits the capacity to activate NRF2 signaling, making it a valuable compound for investigating glycolysis modulation in scientific research [1].

CBR-470-1 是一种有效的糖酵解磷酸甘油酸激酶1 (PGK1) 抑制剂，通过增加甲基乙二醛的水平来激活 NRF2。 CBR-470-1 是一种非共价的 Nrf2 激活剂，具有神经保护活性，通过激活 Keap1-Nrf2 级联反应来保护 SH-SY5Y 神经元细胞免受 MPP+ 诱导的细胞毒性。

CBR-3465 是结核分枝杆菌 (Mtb) II 型 NADH 脱氢酶的有效抑制剂。CBR-3465 抑制结核分枝杆菌的 MIC 值为 0.16 μM。

CBR-6672, a type II NADH dehydrogenase inhibitor, demonstrates potent antimycobacterial activity against mycobacterium tuberculosis (Mtb) with a minimum inhibitory concentration (MIC) of 0.14 μM [1].

CBR Agonist-1 (27a-cis) 是一种大麻素受体 (CBR) 激动剂，能够作用于 CB1R (Ki: 0.18 μM) 和 CB2R (Ki: 1.22 μM)。CBR Agonist-1 (27a-cis) 能够用于研究内源性大麻素系统相关疾病。

CBR Agonist-2 是一种 CB1 激动剂 (EC50: 960 nM)(Ki: 970 nM)(CB1R; CB1 配体)。CBR Agonist-2 是一种很有前景的工具，能够用于 hCB1R 参与的内源性大麻素系统相关疾病的研究。

PROTAC BRD4 ligand-1 是 PROTAC GNE-987 靶向 BRD4 蛋白的配体，也是一种 BET 的抑制剂。

MTOB (α-keto-γ-Methylthiobutyric acid) 是 c 末端结合蛋白 (CtBP) 的底物，可干扰 CtBP 在细胞培养物和小鼠中的致癌活性。它还积极调节 TCF-4 信号传导，导致癌症干细胞 (CSC) 生长和自我更新。

Pidotimod 是一种具有免疫调节特性的合成二肽。它增加巨噬细胞活性和体液免疫功能。它可研究慢性支气管炎、慢性阻塞性肺疾病 、支气管扩张、慢性特发性荨麻疹等。

PROTAC B-Raf degrader 1 is a proteolysis targeting chimera (PROTAC) for the degradation of B-Raf,PROTAC B-Raf degrader 1 With anti-cancer activity.

PROTAC BRD9 Degrader-1 is a leading PROTAC BRD9 chemical degrader with an IC50 of 13.5 nM.

I-BET762 carboxylic acid is an inhibitor of BRD4(pIC50 of 5.1).

PROTAC BRD4 Degrader-1 is an efficacious degrader of BRD4(BRD4 BD1,IC50 of 41.8 nM).

PROTAC BRD4 Degrader-2 is an efficacious degrader of PROTAC BRD4(BRD4 BD1,IC50 of 14.2 nM).

PROTAC BRD4 Degrader-3 is an efficacious degrader of PROTAC BRD4.

PROTAC BRD9-binding moiety 1 that binds to BRD9, and used for inhibiting BRD9 activity, based on PROTAC.

PROTAC BRD9-binding moiety 1 hydrochloride inhibits BRD9 activity by binding to BRD9, utilizing the PROTAC (Proteolysis Targeting Chimera) mechanism.

Candesartan (CV 11974) 是一种血管紧张素II 受体拮抗剂(IC50:0.26 nM)。

IA-Alkyne (Iodoacetamide-alkyne) 是TRP 通道 (TRPC) 的激动剂，有用于呼吸道感染相关疾病研究的潜力。IA-Alkyne 可以用于开发同位素标记的探针，在定量的半胱氨酸反应分析 (cysteine-reactivity)有应用的价值。

PROTAC BRD2/BRD4 degrader-1 (compound 15) serves as a potent, selective degrader of BET proteins BRD4 and BRD2, achieving rapid, reversible, and unexpectedly selective elimination of BRD4 and BRD2 compared to BRD3. Its efficacy in suppressing solid tumors manifest with minimal cytotoxic effects. This compound comprises a BET inhibitor, a connecting linker, and thalidomide as the ligand for cereblon (CRBN)/cullin 4A[1].

PROTAC BRD4-binding moiety 1 is a BRD4 ligand that binds to the cereblon ligand through a linker, enabling the formation of a PROTAC complex. This complex efficiently degrades BRD4[1].

Desmethyl-QCA276, the QCA276-based moiety, binds to cereblon ligand via a linker to form PROTAC to degrade BET. QCA276 is a BET inhibitor with an IC50 of 10 nM, and with a Ki of 2.3 nM[1].